WhiteLab Genomics Raises €23.2M to Accelerate Genomic Medicine
WhiteLab Genomics raised €23.2M Series B led by AVP to expand in vivo validation and global biopharma partnerships.
The big picture: WhiteLab Genomics, a Paris-based biotech company leveraging AI for genomic medicine design, has closed a €23.2 million ($26 million) Series B funding round.
Why it matters:
- Precision Delivery: Genomic medicines face a critical challenge in safely and effectively delivering therapies to target cells; WhiteLab’s platform addresses this by designing optimized viral and non-viral delivery vehicles.
- In Vivo Validation: The company focuses on experimental validation in living systems, moving beyond theoretical designs to demonstrate tangible results, including crossing the blood-brain barrier for difficult-to-treat neurological conditions.
- Global Expansion: This funding will fuel the expansion of WhiteLab’s in vivo validation work, strengthen its North American presence, and explore new markets in Asia, positioning it for broader biopharma partnerships.
How it works:
- AI-Led Design: WhiteLab utilizes its proprietary ALFRED (AI-Led Framework for Rational Exploration in Drug Design) platform to design and optimize both delivery vehicles (like AAVs and lipid nanoparticles) and programmable genetic payloads.
- Experimental Proof: The platform’s designs are rigorously tested and validated in vivo, as demonstrated by its collaboration with the Paris Brain Institute, where engineered AAVs showed strong brain-to-liver targeting.
- Broadening Scope: The new capital will enable WhiteLab to extend its in vivo validation beyond AAVs to non-viral delivery technologies and synthetic promoters, building a diverse portfolio of validated bio-assets.
The catch: While WhiteLab Genomics has demonstrated promising in vivo results, the competitive landscape of AI-driven drug discovery is rapidly evolving, with numerous players vying for breakthroughs in genomic medicine. Scaling in vivo validation across multiple technologies and securing significant biopharma partnerships will be crucial for sustained market leadership, especially as global expansion introduces new regulatory and market complexities.
Key Facts
- Company: WhiteLab Genomics
- Amount: €23.2M
- Round: Series B
- Investors: AVP (lead), Yaday Health, Blast Club, Omnes Capital, Debiopharm Innovation Fund
- Founders: David Del Bourgo, Lucia Cinque, Julien Cottineau
- Sector: AI-driven Genomic Medicine
- Headquarters: Paris, France
Funding Weekly
Every AI funding round we reported last week: the totals, the biggest deals and what they add up to. Weekly · Tuesdays.